Nomination Committee appointed for the Annual General Meeting 2022

Regulatory

The Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Friday 29 April 2022 at the company’s headoffice in Tullinge, has been appointed. The Nomination Committee for the 2022 AGM in Bactiguard Holding AB (publ) will consist of the following members: Helena Borglund, appointed by TomBact...

Interim report for Q3 2021

Regulatory

Capital injection initiates a new phase of accelerated expansion Third quarter (July-September 2021) Revenues amounted to SEK 45.2 (34.1) million, an increase of 32%. Adjusted for currency effects revenues increased by 36%. EBITDA amounted to SEK 1.2 (-3.1) million with an EBITDA margin of 3% (-9%). Operating profit amounted to SEK -10.7 (-14.3)...

Increased number of shares and votes in Bactiguard

Regulatory

The number of shares and votes in Bactiguard Holding AB has changed due to the recently completed directed share issue. Through the directed share issue, the number of class B shares and votes in Bactiguard has increased by 1,500,000.As of today, the last trading day of the month, the total number of shares in Bactiguard amounts to 35,043,885, of...

Bactiguard completes a directed new share issue to AMF, raising approximately SEK 228 million

Regulatory

The board of directors of Bactiguard Holding AB (publ) (“Bactiguard”) has resolved on a directed new share issue of 1,500,000 B shares at a price of SEK 152 per share, corresponding to approximately SEK 228 million. The Board of Directors of Bactiguard has, based on the authorisation granted by the general meeting on April 28, 2021, resolved...

Bactiguard appoints new CEO

Regulatory

The Board of Bactiguard Holding AB (publ) has today appointed Anders Göransson as the new CEO. Anders has extensive experience from consulting within McKinsey and has held several senior positions in Amgen, most recently as Head of Innovation Europe. Anders will start his employment in Bactiguard immediately and take up the role of CEO on 1...

Interim report for Q2 2021

Regulatory

Major progress in the licensing business and several new partnerships for wound care Second quarter (April-June 2021) Revenues amounted to SEK 46.0 (48.2) million, a decrease of 5%. Adjusted for currencies revenues increased 5%. EBITDA amounted to SEK 1.8 (10.5) million with an EBITDA margin of 4% (22%). Operating profit amounted to SEK -10.0...

Bactiguard receives payment from Zimmer Biomet

Regulatory

Following successful European regulatory clearance and market launch of Bactiguard-coated Zimmer Biomet trauma implants (ZNN Bactiguard), the initial USD 1 million milestone payment has been released. “I am excited about our partnership with Zimmer Biomet and proud of the progress we have made thus far”, says Cecilia Edström,...

Bulletin from Bactiguard Holding AB’s (publ) Annual General Meeting

Regulatory

At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 28 April 2021, the following resolutions were made: The AGM adopted the income statements and balance sheets for 2020 and decided that no dividend for the financial year 2020 will be paid. Retained earnings and the company's result for the year will be carried forward. The Board...

Interim report for Q1 2021

Regulatory

Continued high activity in the first quarter – infection prevention a global sustainability issue First quarter (January-March 2021) Revenues amounted to SEK 41.8 (48.1) million, a decrease by 13%. Adjusted for currencies the decrease was 3%. EBITDA amounted to SEK 1.9 (14.4) million with an EBITDA-margin of 5% (30%). Operating profit amounted...

Bactiguard’s Annual Report 2020

Regulatory

The annual report for Bactiguard Holding AB (publ) 2020 is now available at www.bactiguard.com. The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from April 28 and can be ordered by sending an email to: info@bactiguard.com. This information is...

Notice to attend the Annual General Meeting of Bactiguard Holding AB

Regulatory

The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting (AGM) to be held on Wednesday, 28 April 2021. Due to the ongoing pandemic, the Company’s board of directors has decided that the AGM will be conducted without the physical presence of...

Year-end report 2020 Bactiguard Holding AB

Regulatory

Recovery in the fourth quarter – Infection prevention key in future healthcare Fourth quarter (October-December 2020) Revenues amounted to SEK 55.6 (59.8) million, a decrease by 7% (adjusted for currency -2%). EBITDA amounted to SEK 4.9 (12.2) million with an EBITDA-margin of 9% (20%). Operating profit amounted to SEK -6.4 (1.7) million. Net...

Thomas von Koch proposed as new Chairman of the Board

Regulatory

The Nomination Committee of Bactiguard Holding AB (publ) has today held a meeting and decided to propose Thomas von Koch as new Chairman of the Board at the Annual General Meeting on April 28, 2021. The current Chairman of the Board, Christian Kinch, is proposed by the Nomination Committee as new Deputy Chairman of the Board. Cecilia Edström has...

Cecilia Edström resigns as CEO of Bactiguard

Regulatory

Cecilia Edström has today informed the Board that she wishes to resign as CEO of Bactiguard Holding AB (publ) after seven years in the Executive Management team. The Board will therefore initiate the recruitment of a new CEO. Cecilia Edström will continue in her role as CEO until her successor has been appointed and is available for re-election...

Bactiguard-coated Zimmer Biomet trauma implants receive European regulatory clearance

Regulatory

Today, Bactiguard-coated Zimmer Biomet orthopaedic trauma implants received European regulatory clearance and CE mark. Preparations for registering the implants in the U.S. market are also ongoing.“I am very pleased that the CE mark has been secured for Bactiguard-coated Zimmer Biomet trauma implants. This clearance will pave the way for...

New order from China

Regulatory

Bactiguard has received an initial order for coating concentrate from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate license revenues in the fourth quarter 2020 of approximately SEK 9 million. In parallel with the marketing and sales of Bactiguard's BIP Foley...

Interim report for Q3 2020

Regulatory

Weak quarter but the need for infection prevention greater than ever. Third quarter (July-September 2020) Revenues amounted to SEK 34,1 (67,2) million a decreased by 49% (adjusted for currency -46%) due to Covid-19 effects on both license and BIP revenues. In addition, no new license revenue was generated within the quarter while the third...

Bactiguard maintains clear growth strategy and updates financial targets

Regulatory

Bactiguard presents updated financial targets for 2025 in connection with the company's financial report for the third quarter of 2020.Bactiguard's growth strategy for the coming five-year period up to 2025 is based on a continued roll-out of Bactiguard's technology, with a focus on new license agreements and a broader product portfolio. “We are...

Nomination Committee appointed for the Annual General Meeting 2021

Regulatory

The Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Wednesday 28 April 2021 at the company’s headoffice in Botkyrka, has been appoined. The Nomination Committee for the 2021 AGM in Bactiguard Holding AB (publ) will consist of the following members: Helena Borglund, appointed by KK Invest...

Interim report for Q2 2020

Regulatory

Strong growth and earnings development in quarter affected by COVID-19 Second quarter (April-June 2020) Revenues amounted to SEK 48,2 (33,0) million and increased by 46% (adjusted for currency 45%). EBITDA amounted to SEK 10,5 (5,7) million with an EBITDA-margin of 22% (17%). Operating profit amounted to SEK -0,8 (-4,8) million. Net profit/loss...

Bactiguard initiates collaboration with online pharmacy Apotea on sales of Hydrocyn® aqua

Regulatory

Bactiguard initiates collaboration with the online pharmacy Apotea on sales of Hydrocyn® aqua (Hydrocyn) to consumers in the Swedish market. Recent tests confirm that Hydrocyn is the first disinfectant on the Swedish market with documentet effect on the new Corona virus causing COVID-19. Sales via Apotea will commence on 5 June. “We are...

Hydrocyn® aqua inactivates the coronavirus causing COVID-19

Regulatory

The effect of Hydrocyn® aqua (Hydrocyn) on the new coronavirus (SARS-CoV-2) causing COVID-19 has been confirmed. Tests performed by the Swedish National Veterinary Institute show that 99.9% of the virus particles were killed after exposure to Hydrocyn. Bactiguard launched Hydrocyn in the Swedish market in March, with focus on critical societal...

Increased number of shares and votes in Bactiguard

Regulatory

During May 2020, the number of class B shares in Bactiguard Holding AB (publ) ("Bactiguard") has increased by 241,512. As a result, the total number of shares in the company as of May 29, 2020 amounted to 29,543,885 and the total number of votes to 69,543,885.The increase is a result of the new issue of shares by way of set-off that was approved...

Interim report for Q1 2020

Regulatory

The development of the Covid-19 pandemic has painfully highlighted the urgent need for infection prevention. This has led to an increased interest in Bactiguard and generated strong sales from mid-March. Total revenues increased by more than 40 percent in the quarter and EBITDA doubled, generating an EBITDA margin of 30 percent and a positive net...

Bactiguard appoints Gabriella Björknert Caracciolo as new CFO

Regulatory

Bactiguard Holding AB (publ) has appointed Gabriella Björknert Caracciolo, currently Head of Strategy, Development and Governance within Transaction Banking, Nordea as new CFO and Executive Vice President. She succeeds Cecilia Edström, who in February was appointed CEO of the company. Gabriella Björknert Caracciolo assumes her new position in...

Bulletin from Bactiguard Holding AB’s (publ) Annual General Meeting 2020

Regulatory

At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 28 April, 2020, the following resolutions were made: The AGM adopted the income statements and balance sheets for 2019 and decided that no dividend for the financial year 2019 will be paid. Share premium reserve, retained earnings and the company's loss for the year will be...

Information about the Annual General Meeting 2020 and invitation to CEO presentation

Regulatory

The Annual General Meeting will be held on Tuesday, 28 April 2020 at 2:00 pm at the company´s head office at Alfred Nobels Allé 150 in Tullinge. Due to the outbreak of the Covid-19 virus and for the safety of Bactiguard shareholders, the company urges all shareholders not to participate personally, but instead take advantage of the opportunity...

Bactiguard’s Annual Report 2019

Regulatory

The annual report for Bactiguard Holding AB (publ) 2019 is now available at www.bactiguard.com The annual report in Swedish is now available as a downloadable PDF document. An English version will be available shortly. A printed version of the report will be available from April 28 and can be ordered by email to: info@bactiguard.se. This...

Notice to attend the Annual General Meeting of Bactiguard Holding AB 2020

Regulatory

The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting to be held on Tuesday, 28 April 2020 at 2:00 pm at the company´s head office at Alfred Nobels Allé 150 in Tullinge. Registration will commence at 1 pm. Right to participate and notice of...

Year-end report 2019 Bactiguard Holding AB

Regulatory

A strong development in fourth quarter earnings, combined with the licensing deal with Zimmer Biomet led to the highest full-year result in Bactiguard's history. The financial effects of both increased BIP sales and new license revenues clearly show that our growth strategy works.Fourth quarter (October-December 2019) Revenues amounted to SEK 61.6...

Christian Kinch resigns as CEO of Bactiguard and is proposed as new Chairman of the Board. Cecilia Edström appointed new CEO.

Regulatory

Christian Kinch today announced to the Board that he will resign as CEO of Bactiguard Holding AB (publ) after close to 16 years. The Board has appointed CFO and Deputy CEO Cecilia Edström as new CEO of Bactiguard and Stefan Grass (CMO) as Deputy CEO. Until a permanent CFO has been recruited, Financial manager Lina Arverud will hold the position...

Bactiguard makes its first acquisition by acquiring Vigilenz

Regulatory

Bactiguard deepens the partnership that was initiated in 2015 by acquiring Vigilenz Medical Devices and Vigilenz Medical Supplies (together Vigilenz) in Malaysia. The acquisition strengthens Bactiguard’s position in infection control and wound management, as well as innovation and product development capability and capacity. The...

New major order from China

Regulatory

Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the fourth quarter of approximately SEK 16.5 million.”This is the second order from Well Lead outside the initial contract and further strengthens that end-customer sales in China are picking up. At the...

Interim report for Q3 2019

Regulatory

The new license agreement with Zimmer Biomet contributed to that we delivered the strongest quarter to date for Bactiguard as a listed company. The partnership with one of the three largest orthopedic companies in the world confirms the strength of Bactiguard's technology in a global perspective and a new medical application for long-term...

Nomination Committee appointed for the Annual General Meeting 2020

Regulatory

The members of the Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Tuesday 28 April 2020 at the company’s headoffice in Botkyrka, have now been appoined.The Nomination Committee for the 2020 Annual General Meeting in Bactiguard Holding AB (publ) will consist of the following members: Jan...

New major order from China

Regulatory

Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the third quarter of approximately SEK 4,8 million.”The order we have just received from Well Lead is the first outside of the initial contract and therefore an important milestone in our cooperation,...

Bactiguard signs global license agreement with Zimmer Biomet

Regulatory

Bactiguard has entered into an exclusive, global license agreement for orthopedic trauma implants with Zimmer Biomet. The agreement includes an upfront license fee of USD 3 million payable at signing, additional contingent payments of USD 2 million, based on U.S. regulatory clearance and royalties on net sales following commercialization. “Our...

Interim report for Q2 2019

Regulatory

The second quarter of 2019 was eventful. We increased our market coverage, secured funding for a very interesting research and development project, broadened the clinical evidence and strengthened executive management. Revenues and earnings were weaker than last year, but one must bear in mind that the second quarter 2018 was very strong.Second...

CFO Cecilia Edström appointed deputy CEO

Regulatory

The Board of Directors has appointed Chief Financial Officer (CFO) Cecilia Edström deputy CEO of Bactiguard, in addition to her current responsibilities.”Cecilia Edström was recruited to Bactiguard ahead of the IPO in 2014 and has had several roles in the company since then. This means that she has acquired a broad and deep...

Bulletin from Bactiguard Holding AB’s (publ) Annual General Meeting 2019

Regulatory

At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 15 May, 2019 the following resolutions were made: The AGM adopted the income statements and balance sheets for 2018 and decided that no dividend for the financial year 2018 will be paid. Retained earnings and the company's loss for the year will be carried forward. The Board of...

Interim report for Q1 2019

Regulatory

A stable beginning of the yearThe beginning of 2019 was stable. Revenues increased somewhat, while the EBITDA result and margin greatly improved. 2018 was an exciting and eventful year for Bactiguard when we reached several important milestones, so we have high expectations for 2019.First quarter (January-March 2019) Revenues amounted to SEK 35.1...

Bactiguard’s Annual Report 2018

Regulatory

The annual report for Bactiguard Holding AB (publ) 2018 is now available at www.bactiguard.comThe annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from May 15 and can be ordered by email to: info@bactiguard.se. This information is information that Bactiguard...

Notice to attend the Annual General Meeting of Bactiguard Holding AB 2019

Regulatory

The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting to be held on Wednesday, 15 May 2019 at 2:00 pm at the company´s headoffice at Alfred Nobels Allé 150 in Tullinge. Registration will commence at 1 pm. Right to participate and notice of...

Year-end report 2018 Bactiguard Holding AB

Regulatory

2018 was an exciting and eventful year for Bactiguard when we reached several important milestones, primarily strong growth in sales of our own product portfolio for infection prevention (BIP portfolio), the distribution and license agreement with Well Lead for China and the CE mark for orthopaedic trauma implants, which opens possibilities in a...

Bactiguard focuses operations in MEA

Regulatory

Bactiguard focuses operations in the Middle East and transfers its distribution to Iraq to a European distributor that, at the same time, takes over accounts receivable at a book value of SEK 17.1 million. The proceeds amount to SEK 12.8 million and, therefore, a write-down of accounts receivable corresponding to the balance of SEK 4.3 million is...

New major order from China

Regulatory

Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered before the end of the year and generate revenues in the fourth quarter of approximately SEK 10 million.In June 2018, Bactiguard signed a combined distribution and license agreement with Well Lead at an initial value of over 30 million. At...

CE-mark opens the door to billion-dollar market for orthopaedic trauma implants

Regulatory

Orthopaedic trauma implants in titanium with Bactiguard's coating for infection prevention have been CE marked and can, from now on, be sold and used in markets that apply EU quality standards. At the same time, the CE-mark opens possibilities for Bactiguard to establish new license agreements covering more markets. The global market for trauma...

Interim report for Q3 2018

Regulatory

Stable development following a very strong second quarterFollowing a very strong second quarter, the third quarter was a bit calmer, which is natural. Total revenues were somewhat higher than last year primarily due to increased license revenues from our largest partner BD, while BIP sales were lower. It is therefore reassuring that, so far this...

Nomination Committee appointed for the Annual General Meeting 2019

Regulatory

The Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Wednesday 15 May 2019 at the company’s headoffice in Botkyrka, has been appoined. The Nomination Committee for the 2019 AGM in Bactiguard Holding AB (publ) will consist of the following members: Jan Ståhlberg, Chairman of the...

Interim report for Q2 2018

Regulatory

The second quarter of 2018 was eventful and financially strong, both revenue and profitability wise. Sales increased by more than 40 percent, driven by more than a doubling in sales of our own product portfolio. We also signed a combined distribution and licensing agreement for China that contributed new licensing revenues. We generated an EBITDA...

Bactiguard takes the next step in China and signs agreement worth more than SEK 30 million

Regulatory

Bactiguard takes the next step in China and accelerates its ambitions through a combined distribution and license agreement with Well Lead Medical (Well Lead) with an initial value of more than SEK 30 million. At the same time, the cooperation with the current distributor Jian AN is terminated and Bactiguard pays a compensation of approximately...

Bulletin from Bactiguard Holding AB’s (publ) Annual General Meeting 2018

Regulatory

At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 16 May, 2018 the following resolutions were made: The AGM adopted the income statements and balance sheets for 2017 and decided that no dividend for the financial year 2017 will be paid. Retained earnings and the company's loss for the year will be carried forward. The Board of...

Interim report for Q1 2018

Regulatory

In 2018, our primary focus is to generate growth through increased sales of our own product portfolio and by developing new licensing businesses, to approach our financial targets, and contribute to saving more lives. Therefore, it is gratifying that we can already report a strong growth in sales of our own product portfolio, which more than...

Bactiguard’s Annual Report 2017

Regulatory

The annual report for Bactiguard Holding AB (publ) 2017 is now available at www.bactiguard.com The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from May 11 and can be ordered at info@bactiguard.se. This information is information that Bactiguard Holding AB...

New major order from China

Regulatory

Bactiguard has received a new order from China of 100 000 urinary catheters for infection prevention, which will be delivered in March and generate revenues of some 3 million SEK. We have received a new order from our distributor Jian An Pharmaceuticals. The order is for 100 000 Bactiguard coated Foley catheters for infection prevention. The...

Year-end report 2017 Bactiguard Holding AB

Regulatory

2017 was a good year for Bactiguard. Our objective was to generate growth, with sustained cost control, to approach our long-term financial targets of 20 percent growth and an EBITDA margin of 30 percent. It is therefore gratifying that sales for the full year amounted to close to MSEK 154, which means growth of 20 percent, quite in line with our...

The Nomination Committee proposes that Jan Ståhlberg is elected new member of the Board and Chairman of Bactiguard Holding AB (publ)

Regulatory

The Nomination Committee of Bactiguard Holding AB (publ) (Bactiguard) proposes that the Annual General Meeting 2018 elects Jan Ståhlberg as new member and Chairman of the Board, as Stanley Brodén who has been the Chairman of the Board since 2015 has declined reelection. Jan Ståhlberg is Vice Chairman of EQT AB and has been active in EQT since...

New major order from China

Regulatory

Bactiguard has received a new order from China of 100 000 urinary catheters for infection prevention, which will be delivered in December and generate revenues of some 3 million SEK. We have received a new order from our distributor Jian An Pharmaceuticals. The order is for 100 000 Bactiguard coated Foley catheters for infection prevention. The...

Interim report for Q3 2017

Regulatory

We can now put eight quarters of rising sales based on rolling twelve-month figures behind us, which is very positive. This means that more and more patients have access to effective and safe infection prevention, not least in Sweden where we have recently won another tender. The value of delivered products increased by close to 50% in the...

Bactiguard secures three-year financing

Regulatory

Bactiguard has received a commitment for a three-year credit facility of SEK 180 million from Skandinaviska Enskilda Banken (SEB), in the form of an overdraft facility of SEK 30 million and a term loan of SEK 150 million. The credit facility replaces current bank financing as well as a loan from the company's main shareholders. "For some time,...

New major order from China

Regulatory

Bactiguard has received a new order from China of 100 000 urinary catheters for infection prevention, which will be delivered in September and generate revenues of some 3 million SEK. We have received a new order from our distributor Jian An Pharmaceuticals. The order is for 100 000 Bactiguard coated Foley catheters for infection prevention,...

Bactiguard’s central venous catheters approved in India

Regulatory

The product approval for Bactiguard's central venous catheters has been announced by the Indian Ministry of Health & Family Welfare. This provides new opportunities for Bactiguard in providing effective infection prevention in one of the largest and fastest growing markets in the world.  The Central Drugs Standard Control Organisation...

Bactiguard appoints new CFO

Regulatory

Bactiguard Holding AB (publ) has appointed Cecilia Edström, today Senior Vice President Sales and New Business, as acting Chief Financial Officer (CFO). She succeeds Fredrik Järrsten, who will leave Bactiguard to assume a new CFO role in another company. Cecilia Edström will assume her new position on 15 September. ”Fredrik Järrsten has...

Interim report for Q2 2017

Regulatory

Bactiguard saves lives by preventing healthcare associated infections. With the development in the second quarter, sales of our own product portfolio have now increased for seven consecutive quarters, based on rolling twelve-month figures. This means that more patients have access to effective and safe infection prevention. The value of delivered...

New major order from China

Regulatory

Bactiguard has received a third major order from China of 100 000 Bactiguard coated Foley catheters for infection prevention, which will be delivered in June and generate revenues of some 3 million SEK. We have received a third major order from our distributor Jian An Pharmaceuticals. The order is for 100 000 Bactiguard coated Foley catheters...

Interim report for Q1 2017

Regulatory

Strong financial start in 2017. Revenue grew 58 % in the first quarter and we reached an EBITDA margin of 33 %. The reason for the improved results, besides a new licensing deal, is that we have higher revenues from C.R. Bard and continued cost control. The volume of products sold from our own portfolio is lower than last year, but the product...

Year-end report 2016 Bactiguard Holding AB

Regulatory

In many ways, 2016 was a good year for Bactiguard. We exceeded our goal of doubling the volume of products sold in our own portfolio by a wide margin and delivered approx. 418,000 units. We made a breakthrough in China and India, now our two largest markets, and we entered several European markets, while advancing our position in the domestic...

Bactiguard enters new therapeutic area through license agreement with Smartwise AB

Regulatory

Bactiguard and Smartwise Sweden AB (Smartwise) have entered into a joint development project for advanced, Bactiguard-coated vascular injection catheters. At the same time, a license agreement has been signed. Smartwise will pay USD 2.5 million, for the exclusive and global right to the Bactiguard technology for this application, payable in...

Bactiguard enters Germany

Regulatory

Bactiguard has entered into partnership with Roeser Medical GmbH (“Roeser”) and signed an exclusive distribution agreement for Germany and Switzerland. At the same time, an order for products worth some EUR 400 000 has been placed and will be delivered throughout 2017.  Bactiguard’s central European coverage has expanded significantly in...

Bond loan repaid

Regulatory

  Bactiguard outstanding bond loan was repaid in full on 12 December. The refinancing solution consists of loans totaling SEK 150 million.   The bond loan Bactiguard issued in December 2011, with an initial nominal value of SEK 450 million, an annual interest rate of 11% and a duration of 5 years, matured on 12 December. The outstanding...

Exercise of call options

Regulatory

  The call option program established by the main shareholders and aimed at key individuals in Bactiguard, matured on 30 November 2016. During the exercise period, a total of 688 000 B shares were acquired, corresponding to 2.07 percent of the capital and 0.99 percent of the votes, reducing the holdings of the main shareholders accordingly....

Interim report for Q3 2016

Regulatory

  In the third quarter we report a continued positive trend in sales of our own portfolio of infection prevention products for the healthcare sector. We have delivered a total of approx. 284,000 products so far this year, an increase by approx. 260 percent. This means that we are already now close to our goal of at least doubling the...

The main shareholders issue a loan commitment

Regulatory

In order to maintain financial flexibility after the repayment of the bond, and until a long-term financing solution is in place, the main shareholders of Bactiguard have issued a loan commitment of up to SEK 50 million Bactiguard has previously announced that it has secured the refinancing of the bond loan maturing December 12, 2016 through the...

New major order from China

Regulatory

Bactiguard has received a new major order from China of 100 000 Bactiguard coated Foley catheters for infection prevention  We have received a new major order from our distributor in China, Jian An Pharmaceuticals. The order is for 100,000 BIP Foley catheters, which is the same quantity as the initial order received in early 2016. The order will...

Interim report for Q2 2016

Regulatory

  The positive trend with increased sales of our own portfolio of infection prevention products for the healthcare sector has continued and we delivered almost 110 000 units in the quarter. We have delivered a total of approximately 200 000 products so far this year, well above the total annual volume for 2015. License revenues are also back...

New major order from India

Regulatory

  Bactiguard has received a new order from India of some 60 000 Foley catheters for infection prevention.   The initial order from India, which was received in December 2015, consisted of some 50 000 Foley catheters for infection prevention (BIP Foleys). The new order consists of some 60 000 BIP Foleys and will generate direct sales...

Extended maturity for credit facility

Regulatory

The maturity of the credit facility of SEK 100 million that Bactiguard received as a loan commitment in November 2015, has been extended until 31 December, 2017 In November 2015 Bactiguard entered a credit facility agreement of SEK 130 million, consisting of a loan commitment of SEK 100 million and a renewal of bank overdraft facility of SEK 30...

Executive Management Invests in Bactiguard

Regulatory

The Executive Management in Bactiguard has been offered an opportunity to invest in the company by purchasing a sizeable number of shares.  The Executive Management in Bactiguard has been offered an opportunity to invest in the company by purchasing a sizeable number of shares. Other members of senior management have also been offered the...

Bactiguard Holding AB’s (publ) Annual General Meeting

Regulatory

  At Bactiguard Holding AB’s (publ) Annual General Meeting on May 19, the following resolutions were made:   The Annual General Meeting adopted the income statement and balance sheet for 2015. It was decided that no dividend for the financial year 2015 will be paid and that the company's loss (for the year) will be carried forward....

Interim report for Q1 2016

Regulatory

Bactiguard started the year by increasing sales of its own product portfolio and delivered approx. 87,600 units, which is more than half of the total volume in 2015. License revenues were lower due to the adjusted order from C.R Bard, but as of March the order situation is back at a stable level. Operating profit was negative, but mayor payments...

Bactiguard’s Annual Report 2015

Regulatory

The annual report for Bactiguard Holding AB (publ) 2015 is now available at www.bactiguard.com The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from May 10 and can be ordered at info@bactiguard.se. This is information that Bactiguard Holding AB (publ) is...

Notice to attend the Annual General Meeting of Bactiguard Holding AB 2016

Regulatory

The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”), are hereby given notice to attend the Annual General Meeting to be held on Thursday, 19 May 2016 at 2:00 PM at the company´s office at Alfred Nobels Allé 150 in Tullinge. Registration commences at 1 PM. Right to participate and notice of intent to...

A year of positive volume and earnings growth, ending with the product approval in China

Regulatory

2015 ended with the long-awaited product approval in China and a first order from India. As a result of large deliveries in the fourth quarter we doubled the total volume of units shipped, compared with the year before. An additional order from C.R. Bard generated additional revenue and strengthened the result. A new licensing deal opened...

Invitation to presentation of Bactiguard’s year end report for 2015 on February 18

Regulatory

Bactiguard Holding AB publishes the year end report for 2015 on Thursday February 18 at 08:00 CET In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on February 18. CEO Christian Kinch and CFO Fredrik Järrsten will present the report and answer questions. The year end report will be available...

First order from China

Regulatory

Following the Chinese approval of Bactiguard’s Foley catheters for infection prevention, which was recently announced, the company has received an initial order of 100,000 catheters.  In January 2016, the doors were opened to China, one of the largest and fastest growing markets in the world, with the approval of the company's Foley catheter...

Product approval opens door to China

Regulatory

The product approval for Bactiguard's foley catheters for infection prevention in China, has now been announced by China Food and Drug Administration (CFDA). This opens the door to one of the largest and fastest growing markets in the world. ”Finally a breakthrough for Bactiguard in China. We started the approval process with CFDA already in...

Adjusted additional order from Bard

Regulatory

In August 2015, Bactiguard received a one off order from C.R. Bard (Bard), intended to increase their safety stock, which generated additional sales of approximately 28 MSEK in the third quarter. Bard has subsequently revised their need of safety stock. This adjustment will have a negative impact on Bactiguard’s revenues of approximately 8...

Changes to the Nomination Committee appointed for the Annual General Meeting 2016

Regulatory

Attorney Jan Lombach will replace Christian Kinch and has also been appointed chairman of the Nomination Committee. Following these changes, the Nomination Committee for the 2016 AGM in Bactiguard Holding AB (publ) will consists of the following members: Stanley Brodén, Chairman of the Board of Directors Jan Lombach, appointed by KK Invest AB,...

Large clinical study starting in India

Regulatory

The planned multi-center clinical study in India has been initiated and the first patients recruited at two reputable hospitals. The purpose of the study is to further validate the efficiency and patient safety of Bactiguard’s Foley catheters in the prevention of catheter-related urinary tract infections. Healthcare associated infections are a...

Major order from India

Regulatory

Bactiguard has received a major order from India of some 50 000 Foleys for infection prevention. At the same time, the planned clinical study has been initiated. The first order from India consists of some 50 000 Foley catheters for infection protection (BIP Foleys) and generates direct sales revenues of close to 2 million SEK, at product...

Growing interest in infection prevention in the Middle East

Regulatory

Bactiguard has received an order from the Middle East, comprising 2 000 central venous catheters (BIP CVC) and 20 000 Foleys (BIP Foley). The delivery will take place before the end of the year. The Middle East is one of Bactiguard’s focus markets and continues to generate repeat orders, so far primarily of Foley catheters. There is a growing...

Nomination Committee appointed for the Annual General Meeting 2016

Regulatory

The Annual General Meeting in Bactiguard Holding AB (publ) will be held on Thursday 19 May, 2016 in Botkyrka. At the Annual General Meeting (AGM) in 2015, it was resolved that the Nomination Committee in Bactiguard Holding AB (publ) shall consist of four members. The chairman of the Board of Directors shall contact the three largest shareholders...

Breaking new ground and strengthening the financial position

Regulatory

Third Quarter (July-September 2015) Revenues amounted to SEK 61.4 (28.1) million. The increase (118 %) compared to the corresponding quarter 2014 is mainly attributable to the additional order from C.R. Bard. EBITDA amounted to SEK 33.9 (2.2) million. Operating profit amounted to SEK 25.7 (-5.3) million. Reported net profit for the quarter...

Bactiguard enters new therapeutic area through license agreement

Regulatory

Bactiguard and Vigilenz Medical Devices (Vigilenz), a Malaysian supplier of medical and surgical products, have entered into a license agreement for Bactiguard coated orthopaedic implants, covering the Asean region. Bactiguard aims to expand its licensing business to new therapeutic areas and Vigilenz’ ambition is to enhance its existing...

Bactiguard secures financing

Regulatory

Bactiguard has entered a credit facility agreement of 130 million SEK in total. Combined with the company’s cash position, the credit facility secures the refinancing of Bactiguard’s bond loan, which matures in December 2016. During the autumn, Bactiguard has been working on securing the refinancing of its bond loan. The income received in...

Positive volume development and continued focus on growth

Regulatory

Second Quarter (April-June 2015) During the second quarter, a total of approx. 58,000 (44,000) BIP products were delivered. Revenues amounted to SEK 27.7 (31.2) million. EBITDA amounted to SEK -10.0 (2.2) million. Provisions for severance pay to the former CEO as well as for doubtful accounts receivable have negatively affected EBITDA during the...

Additional order from Bard

Regulatory

Bactiguard has received a major, one off order from C.R. Bard (Bard) intended to increase their safety stock of Bactiguard-coated Foleys for infection control. The order will generate additional sales for Bactiguard of approximately 28 MSEK in the third quarter and make a positive contribution to cash flow. The additional order will lead to...

Delivery to Saudi Arabia

Regulatory

Bactiguard delivers an order of more than 20 000 Foley catheters for infection control to Saudi Arabia. At the end of June, Bactiguard delivered an order of more than 20 000 Foley catheters to Gulf Medical in Saudi Arabia. Gulf Medical distributes Bactiguard’s portfolio of products for infection control to the healthcare system in both Saudia...

CEO Niels Christiansen leaves Bactiguard

Regulatory

Niels Christiansen leaves his position as CEO of Bactiguard Holding AB (publ) with immediate effect. The Board has appointed Christian Kinch, currently Chairman of the Board, as new CEO. Stanley Brodén has been appointed Chairman of the Board until the Annual General Meeting (AGM) in 2016. “The recruitment of Niels Christiansen as CEO was...

Bactiguard Holding AB’s (publ) Annual General Meeting

Regulatory

At Bactiguard Holding AB’s (publ) Annual General Meeting on May 21, the following resolutions were made: The Annual General Meeting adopted the income statement and balance sheet for 2014. It was decided that no dividend for the financial year 2014 will be paid and that the company's loss (for the year) will be carried forward. The Board of...

Focus on fewer markets, sales and improved cost efficiency

Regulatory

First quarter (January-March 2015) Revenues amounted to SEK 28.8 (34.5) million EBITDA amounted to SEK -26.8 (9.8) million. A changed market strategy for Russia and India has led to provisions for doubtful receivables. These provisions, together with non-recurring costs attributable to a strategic marketing project, have negatively affected EBITDA...

Invitation to presentation of Bactiguard’s interim report on May 12

Regulatory

Bactiguard Holding AB publishes the interim report for the first quarter on Tuesday 12 May at 8:00 CET In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on May 12. CEO Niels Christiansen and CFO Fredrik Järrsten will present the interim report and answer questions. The report and a...

Bactiguard enters distribution agreement for Israel

Regulatory

Bactiguard has entered an exclusive distribution agreement for Israel with Dover Medical & Scientific Equipment Ltd. The agreement covers sales of all products in the Bactiguard Infection Protection portfolio.  “Changing our market strategy for Israel from direct sales to sales via a distributor is a more cost efficient way of expanding...

Delivery to Southern Africa

Regulatory

Bactiguard delivers an order of some 20 000 products for infection control to Southern Africa, comprising both Foley and central venous catheters for the healthcare system in Angola. In July 2014, Bactiguard expanded its market presence to seven countries in Sub-Saharan Africa and made an initial delivery of Foley catheters to Zambia. The...

Welcome to Bactiguard’s Annual General Meeting

Regulatory

The annual general meeting of Bactiguard Holding AB (publ), (“Bactiguard”), will be held on Thursday, 21 May 2015 at 2:00 pm at Vasagatan 7 in Stockholm, in the Vasa Hall. Registration commences at 1:00pm and coffee will be served before the meeting.  Shareholders right to participate and notification Shareholders wishing to participate at...

Bactiguard’s Annual Report 2014

Regulatory

The annual report for Bactiguard Holding AB (publ) 2014 is now available at www.bactiguard.com The annual report is available in both a Swedish and English online version and as a downloadable PDF document. A printed version of the report will be available from  6 May and can be ordered at info@bactiguard.se. This is information that Bactiguard...

Bactiguard changes strategy for Russia and India

Regulatory

Bactiguard has terminated the distribution agreement for Russia and evaluates an alternative sales strategy for India. In connection with the above, the company has decided to make reservations in the interim results for the first quarter of 2015 for doubtful receivables, with a negative effect on results of approximately MSEK 24.  During the...

Bactiguard expands in Europe – new distribution agreement for Switzerland

Regulatory

Bactiguard expands in Europe by entering an exclusive distribution agreement for Switzerland, covering all products in the Bactiguard Infection Protection portfolio. “We are delighted about our expansion in Switzerland, a market recognized for its high quality healthcare. We have managed to break into one of Europe's toughest markets, which...

An eventful year, focused on building a platform for future growth

Regulatory

Fourth quarter (October-December 2014) Revenues amounted to SEK 25.1 (47.9) million EBITDA amounted to SEK -3.9 (25.2) million Reported net profit for the quarter amounted to SEK -15.7 (18.9) million, corresponding to SEK -0.47 (0.95) per share. Net profit for the quarter has been negatively affected by market valuation of the bond with SEK -1.1...

Invitation to presentation of Bactiguard’s year end report for 2014 on February 19

Regulatory

Bactiguard Holding AB publishes the year end report for 2014 on Thursday 19 November at 08:00 CET In connection with this, a conference call for analysts and media will be held at 10:00 CEO on February 19. CEO Johan Rugfelt and CFO Fredrik Järrsten will present the report and answer questions. The year end report will be available at...

Niels Christiansen appointed new CEO of Bactiguard

Regulatory

The Board of Directors has appointed Niels Christiansen as the new CEO of Bactiguard. Niels Christiansen has extensive management experience from various positions in the medical device, life science and energy sectors, most recently as the CEO of HemoCue AB. He will assume his new position in Bactiguard on March 16. At that time, Johan Rugfelt...

Nomination Committee appointed for the Annual General Meeting 2015

Regulatory

The Annual General Meeting in Bactiguard Holding AB (publ) will be held on Thursday 21 May, 2015 in Stockholm. At the Annual General Meeting (AGM) in 2014, it was resolved that the Nomination Committee in Bactiguard Holding AB (publ) shall be formed in a process where the Chairman of the Board contacts the three largest shareholders, based on...

Bactiguard strengthens the organization for the next development phase

Regulatory

Third quarter (July-September 2014) Revenues amounted to SEK 28.1 (32.5) million, a decrease of 14 % over the corresponding quarter last year EBITDA amounted to SEK 2.2 (4.7) million, a decrease of 53 % over the corresponding quarter last year Reported net profit for the quarter amounted to SEK -15.7 (-5.1) million, corresponding to SEK   -0.47...

Invitation to presentation of Bactiguard’s interim report on November 14

Regulatory

Bactiguard Holding AB publishes the interim report for the third quarter on Friday 14 November at 08:00 CET In connection with this, a conference call for analysts and media will be held at 10:00 CEO on November 14. CEO Johan Rugfelt and CFO Fredrik Järrsten will present the interim report and answer questions. The report will be available at...

Bactiguard recruits new Head of Marketing

Regulatory

Bactiguard strengthens its sales and marketing organization by recruiting Nina Nilsson as Head of Marketing. In addition to marketing, she will also focus on developing the Swedish market. Bactiguard is in a rapid expansion phase. Building strong marketing and sales capabilities to support our distributors across the world and develop direct...

Bactiguard expands its market presence in Europe

Regulatory

Bactiguard establishes market presence in Portugal by entering an exclusive distribution agreement with Socime Medical Ltd, covering all products in the Bactiguard infection protection portfolio. Expanding our geographical footprint in Europe is an important part of Bactiguard’s strategy. By entering the Portuguese market we take an important...

Bactiguard reports increased revenues and improved EBITDA for the second quarter 2014

Regulatory

Second quarter (April-June 2014) Revenues amounted to SEK 31.2 (22.1) million, an increase of 41% over the corresponding period last year EBITDA, excluding costs related to the IPO, amounted to SEK 5.2 (3.8) million, an increase of 36% Net profit for the quarter amounted to SEK -44.1 (-13.8) million, corresponding to SEK -2.04 (-0.69) per share,...

Invitation to presentation of Bactiguard’s interim report for the second quarter on August 15

Regulatory

Bactiguard Holding AB publishes the interim report for the second quarter 2014 on August 15 at 08:00 CET.  In connection with this, a telephone conference for analysts and media will be held at 10:00 CET on August 15. CEO Johan Rugfelt and CFO Fredrik Järrsten will present the interim report and answer questions. The report will be available at...

Notice of price stabilization in Bactiguard Holding

Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. Swedbank AB (publ) (”Swedbank”) has exercised the possibility to, in connection with the initial public offering (“IPO”) of Bactiguard Holding AB (publ) (“Bactiguard” or the”Company”), exercise price stabilization...

Bactiguard strengthens its sales organization by appointing Erik Düring head of European sales

Regulatory

Bactiguard is expanding its business, with focus on Europe, the Middle East, Asia, South America and Southern Africa. The recruitment of Erik Düring as Regional Sales Director Europe is an important step in strengthening the sales and marketing organization, which supports the company’s distributors and develops the markets where Bactiguard...

Bactiguard expands market presence in Southern Africa

Regulatory

Bactiguard establishes market presence in Southern Africa and has entered into exclusive distribution agreements, covering seven sub-Saharan countries and Bactiguard’s complete portfolio of solutions for infection control. An initial order for Foley catheters has already been shipped to Zambia. The order is for Foley catheters, primarily...

Increased number of shares and votes in Bactiguard Holding AB (publ)

Regulatory

In June 2014 the number of shares and votes in Bactiguard has increased by 12,786,373 Class B shares and the same number of votes. As earlier announced, the change in the number of shares and votes is a result of the new issues made in relation to the offer to acquire Class B shares in Bactiguard in connection with the listing of the company's...

Bactiguard prices its initial public offering at SEK 38 per B share – trading commences on NASDAQ OMX Stockholm today

Regulatory

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECLTY, IN USA, AUSTRALIA, CANADA, HONG KONG OR JAPAN. Bactiguard Holding AB (publ) (“Bactiguard” or “The Company”) hereby announces the outcome of the offer to acquire shares in Bactiguard and listing on NASDAQ OMX Stockholm (“the Offer”). Interest in the Offer has been...